NCT01720264View on ClinicalTrials.gov

Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 2, 2012

Primary Completion Date

August 27, 2016

Study Completion Date

December 15, 2017

Conditions
Acute Myeloid LeukemiaAcute Lymphoid LeukemiaHematopoetic MyelodysplasiaLeukemia, Myelogenous, ChronicLymphoma, Non-Hodgkin
Interventions
DRUG

Sitagliptin

Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.

Trial Locations (2)

10595

New York Medical College/Westchester Medical Center/Maria Fareri Children's Hosptial, Valhalla

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Sherif S. Farag

OTHER

NCT01720264 - Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant | Biotech Hunter | Biotech Hunter